Featured/ BIIB/ 07/14/2026 · 10:57 AM Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
